A Toad Less Traveled: Should 5-MeO-DMT Have a Role in Treating Depression?
Psychedelic Medicine April 14, 2025 DOI: 10.1089/psymed.2024.0049 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Topics | 5-MeO-DMT Depression DMT |
| Key points | Argues that 5-MeO-DMT's unusual properties may offer cost-effectiveness and practicality for healthcare providers, but those same features could limit its success as a mainstream antidepressant, and recommends measures for future clinical trials. |
Abstract
As the therapeutic potential of psychedelics is becoming more established, a wider range of compounds are beginning to be investigated for their antidepressant properties. 5-Methoxy- N , N -dimethyltryptamine (5-MeO-DMT) is one such example; its unusual properties may make it a more cost-effective and practical choice for health care providers. However, the same distinctive features may mean that its potential for success as a mainstream treatment option for depression is limited. There is very little existing literature around 5-MeO-DMT, and it is scarcely used even within the psychedelics community. This may mean that it is even more difficult to recruit a diverse range of subjects, which is already an issue for clinical trials involving other psychedelics. The aim of this article is to discuss the hypothetical pros and cons of 5-MeO-DMT as an antidepressant and to make recommendations for measures to be taken in any future clinical trials investigating 5-MeO-DMT.
Comparable studies
Other theoretical and historical papers on 5-MeO-DMT, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| When the Endogenous Hallucinogenic Trace AmineN,N-Dimethyltryptamine Meets the Sigma-1 Receptor | 2009 | Theoretical or philosophical paper | |
| Analytical chemistry of synthetic routes to psychoactive tryptamines : Part I. Characterisation of the Speeter and Anthony synthetic route to 5-methoxy-N,N-diisopropyltryptamine using ESI-MS-MS and ESI-TOF-MS | 2004 | Theoretical or philosophical paper | |
| Enlightening the "Spirit Molecule": Photomodulation of the 5-HT2A Receptor by a Light-Controllable N,N-Dimethyltryptamine Derivative. | 2022 | Theoretical or philosophical paper | |
| Conformational, spectroscopic and nonlinear optical properties of biologically active N,N-dimethyltryptamine molecule: a theoretical study. | 2014 | Theoretical or computational study | |
| Simple syntheses of lespedamine and 5-bromo-n,n-dimethyltryptamine based on 1-hydroxyindole chemistry | 1995 | Theoretical or philosophical paper |
Citations in the library
Cites 41
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine November 3, 2022
- Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Frontiers in Pharmacology January 17, 2018
- Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin Journal of Psychopharmacology October 6, 2015
- Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors Journal of Psychopharmacology October 11, 2017
- Psychedelics, Meditation, and Self-Consciousness Frontiers in Psychology September 4, 2018
and 36 more in the library